Researchers developed a new cancer therapeutic strategy that targets two proteins to improve efficacy and reduce side effects in prostate cancer. The approach demonstrated greater antitumor activity while sparing normal cells, offering a potential more effective treatment strategy.
JMIR Cancer is calling for research on prostate cancer, focusing on digital health innovations, patient perspectives, and AI advancements. Researchers and patients are encouraged to submit their work on topics such as teleoncology, mobile apps, and personalized treatment planning.
The Alliance for Clinical Trials in Oncology is highlighting eight ongoing clinical trials focused on improving cancer detection, treatment, and survivorship for men's cancers. These trials aim to enhance quality of life and support patients and their loved ones after treatment.
The updated guideline recommends moderate hypofractionation over conventional fractionation for patients across all prostate cancer risk groups who choose EBRT, supported by high-quality randomized data showing comparable outcomes, side effects and quality of life. Ultrahypofractionation is also strongly recommended as a standard optio...
A substudy of the PROTEUS regimen found a 62% improvement in event-free survival and a 51% reduced risk of metastasis or death compared to standard of care radical prostatectomy. The combination of apalutamide plus hormone therapy and prostatectomy delayed subsequent therapy by 33 months and reduced the risk of metastases or death by 20%.
A recent analysis reveals a decline in low-risk prostate cancer diagnoses and increased use of active surveillance, indicating a shift away from overtreatment. This change is attributed to growing concerns about overdiagnosis and overtreatment, leading to reduced treatment among patients with low-risk cancers.
A phase 1 trial of the alpha radiopharmaceutical therapy Pb-ADVC001 showed well-tolerated doses and encouraging signs of antitumor activity in patients with advanced prostate cancer. The therapy's optimized dose schedule and 100% overall response rate suggest potential for improved patient outcomes.
A new diagnostic test, Decipher, has shown promise in helping doctors determine which patients with high-risk prostate cancer will benefit from more intensive treatment. The test predicts worse outcomes for patients with higher scores, suggesting that those with low scores may be spared more intensive treatment.
The therapy showed consistent efficacy and a manageable safety profile, with outcomes similar to those in the VISION trial. The findings support the use of PSMA-targeted radiopharmaceutical therapy in routine care for patients with mCRPC, including those eligible for retreatment.
A new study links 12 blood proteins to prostate cancer diagnosed over 15 years after blood sampling, including immune cells and cancer driver genes. The research may help identify men at greater risk of aggressive prostate cancer and inform future studies.
A new AI platform, MAESTRO, has been developed to identify promising drug combinations for overcoming treatment resistance in prostate cancer. The platform uses large language models to analyze scientific knowledge and ranks the most promising candidates, providing a clear biological rationale for experimental testing.
Researchers from the University of East Anglia have discovered 18 new bacterial species collected from prostate cancer patients, including previously linked species like Porphyromonas and Treponema. The study provides new insights into microbes in cancer patients and could uncover links that improve understanding of how cancer develops.
A new UCLA study suggests that adding a targeted radioactive drug to stereotactic body radiation therapy may help delay the spread of recurrent prostate cancer. The treatment showed a 62% lower risk of progression or needing additional hormone therapy, and improved control of disease on conventional imaging.
A study published in Nature reveals that a single transfer RNA (tRNA) plays a crucial role in determining prostate cancer's sensitivity to treatment. The study found that a specific tRNA can control the identity of prostate cancer cells and influence their response to therapy, potentially opening new avenues for precision oncology.
A new study reveals molecular features linked to more aggressive prostate cancer in patients classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies and more precise risk stratification.
A new study finds that PSMA PET/CT-guided targeted biopsy can detect clinically significant prostate cancer in 37% of men, compared to 21% with systematic biopsy alone. Combining the two approaches increases the detection rate to 41%.
Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
A multidisciplinary approach is crucial for treating recurrent prostate cancer, combining advanced imaging, radiation, and systemic therapies to address microscopic disease. The case report follows Larry Hardesty, who underwent several clinical trials, including PSMA-targeted radioligand therapy, leading to undetectable PSA levels and ...
Researchers identified circLPAR3 as a key mediator of docetaxel resistance in prostate cancer, promoting tumor growth under chemotherapy by suppressing ferroptosis. The study highlights circLPAR3 as a promising biomarker for treatment response and suggests targeting its regulatory network could help overcome chemotherapy resistance.
A randomized trial found that five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control and better urinary continence and sexual function compared to surgery. SBRT offered clear advantages for urinary continence and sexual function, with 91% of patients remaining free from biochemical or clin...
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
A large Medicare analysis found that depression is associated with higher cancer mortality, while psychotherapy soon after diagnosis reduces cancer risk. Patients with depression had a 21% lower risk of cancer-specific mortality after receiving psychotherapy within four weeks of their diagnosis.
A new study found that a shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer. However, it was associated with a higher rate of grade 3 urinary adverse events, particularly cystitis and hematuria.
The analysis found that adding short-term androgen deprivation therapy (STADT) to radiation provided a greater benefit for patients with Luminal B tumors compared to those with non-LumB tumors. This suggests that tumor biology can help determine who may benefit from hormone therapy.
A national study of 20,000 men with prostate cancer found that surgery led to higher rates of urinary incontinence and erectile dysfunction, while radiation was associated with urinary complications and higher all-cause mortality. Researchers emphasized that both treatments have long-term consequences and that risks and benefits should...
UCLA researchers present new radiotherapy research for prostate cancer, head and neck cancers, and personalized radiation therapy. A genetic test identifies men with prostate cancer at higher risk of urinary side effects after SBRT, suggesting personalized radiation treatment.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
A study by the Medical University of Vienna shows that PSMA-PET/CT can detect 91% of clinically significant prostate cancers before biopsies, potentially preventing unnecessary procedures. The test's high detection rate and predictive value make it a promising diagnostic tool for suspected prostate cancer.
An international collaboration co-led by the CNIO has identified eight faulty DNA processes driving most prostate cancers, which differ between patients and influence tumor spread. The study offers potential for reliable prognostic markers and personalized treatment, but further validation is needed.
A new study has mapped eight genetic 'fingerprints' that may explain why some men develop aggressive prostate cancer, while others do not. The researchers found that errors during DNA replication play a crucial role in the development of prostate cancer.
A new study found that men with nonmetastatic prostate cancer who replaced saturated and animal fats with unsaturated and plant-based fats had a lower risk of death. Replacing about 10% of daily calories from animal fat with plant-based fat was associated with a 16% lower rate of death.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
A recent survey found that only 20% of men are aware of the potential prostate cancer risk associated with dairy consumption. The survey also showed that 66% of men plan to avoid dairy products after learning about the risk. A meta-analysis of 32 studies supports the link between high dairy intake and increased prostate cancer risk.
The NRG-GU005 trial shows that SBRT improves bowel health related quality of life in localized intermediate risk prostate cancer patients, with no significant impact on urinary HRQOL. SBRT is also associated with lower incontinence related quality of life and improved maintenance of erectile dysfunction compared to hypofractionated IMRT.
Prostate cancer cells rewire amino acid metabolism to override normal brakes on cholesterol production, fueling hormone therapy resistance. Restricting isoleucine and valine in the diet may slow tumor growth and improve treatment response, while boosting propionyl-CoA levels promotes tumor growth.
A retrospective cohort study of 16,924 men found metabolic syndrome and related abnormalities during the first year of treatment. Hypertension was the most common metabolic outcome among patients receiving concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor.
A new study found that the majority of veterans with low-risk prostate cancer pursued active surveillance in 2024, up from 27% in 2005. The study followed over 73,000 veterans and showed similar survival outcomes for surveillance compared to treatment.
A national study found that about half of prostate cancer patients receiving focal therapy fell outside the recommended patient groups, highlighting the need for evidence-based treatment decisions. The study emphasizes the importance of understanding which patients are most likely to benefit from promising new treatments.
A randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer found that stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT for disease-free survival at 3 years. However, SBRT showed better bowel-related quality of life compared to IMRT.
Active surveillance for favorable-risk prostate cancer increased significantly in the Veterans Affairs healthcare system, with high rates among low-risk and intermediate-risk patients. This trend suggests that many veterans are avoiding unnecessary treatment, but disparities in care persist.
This retrospective study examines patterns and trends of focal therapy for nonmetastatic prostate cancer in US cancer centers. Focal therapy procedures remained uncommon, occurring mostly in low-, high-, or very-high-risk disease settings.
A new study from Florida Atlantic University finds that men who consume high amounts of ultra-processed foods have increased risks of prostate cancer. Men with the highest UPF intake had a possible 34% higher risk, although the finding did not reach statistical significance.
Researchers at USC have developed a genetic tool called the Mechano-Recorder to measure tumor cell softness. This insight can help target hard-to-reach cancer stem-like cells for destruction, potentially improving cancer treatment outcomes.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
A new study uses spatial transcriptomics to map the molecular evolution of prostate cancer and identifies key genes associated with disease progression. The research reveals that genetic malignancy in specific glandular epithelial regions tightly aligns with increasing clinical Gleason scores.
A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is associated with improved patient survival, and this cutoff may be the best metric for determining treatment success, according to investigators analyzing Veterans Health Administration data.
A phase 3 clinical trial led by Weill Cornell Medicine shows that adding a targeted radionuclide therapy drug to backbone therapy reduces disease progression in patients with PSMA-positive metastatic prostate cancer. The treatment may delay symptom progression and improve patient outcomes.
A new study uses mathematical biomarkers to accurately predict prostate cancer patient outcomes and survival, outperforming traditional PSA monitoring. These metrics can inform personalized treatment protocols, enabling more effective adaptive therapy.
A team of researchers at UMass Amherst has developed an AI model, DiffuDose, that generates a patient's radiation dose map with gold-standard accuracy in under 23 seconds. This technology has the potential to unlock the full potential of radiopharmaceutical therapy for prostate cancer treatment.
Researchers have identified a promising strategy to improve the effectiveness of targeted therapies in advanced prostate cancer. By combining ADCs with a drug that blocks BCL-XL, they triggered greater cancer cell death and slowed tumor growth. The approach could offer a new strategy for improving antibody-drug conjugates against metas...
A Rice University research team created prostate cancer cells that can survive high-force moments in the body, a process known as mechanoresistance. The study found that a gene called CALB2 plays a key role in this ability, with increased expression linked to metastatic cancer.
Researchers used advanced 3D genome mapping technology to study prostate cancer cells and discovered a new feature of gene control networks that could help fight cancer. The study found that enhancers work cooperatively in 3D networks, with some acting as central hubs that control many genes.
A recent cohort study found similar rates of secondary treatment receipt among men with localized prostate cancer by race, but observed mortality disparities persisted. These findings raise concerns about healthcare inequities and the need for targeted interventions to address racial disparities in cancer care.
A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer most likely to benefit from <sup> 223 </sup> Ra radiopharmaceutical therapy and monitor their progress. The test showed associations between ctDNA profiles and clinical outcomes, including biomarker response and overall survival.
The study found significant progress in reducing cancer mortality disparities for breast and uterine corpus cancers, but persistence in prostate cancer remains. The findings highlight the need for targeted interventions to accelerate progress in equitable cancer prevention and control.
The study creates a radiohybrid approach that labels a single molecule with two different diagnostic radionuclides, enabling long-term visualization of therapeutic agent distribution. This allows for personalized cancer medicine by calculating optimal radiation doses for individual patients.
A new study identifies a rare genetic mutation in the CDK12 gene as a cause of aggressive prostate cancer at a young age. Genetic testing for this mutation could help identify families at risk and support early cancer detection, potentially saving lives.